In a case fraught with implications for the pharmaceutical industry, the U.S. Supreme Court has asked the solicitor general for its views on a lawsuit involving Gilead Sciences (GILD) and what constitutes a material representation by companies that bill the federal government.
The request came in a long-running whistleblower suit that accused the company of misleading regulators about contaminated ingredients used in various HIV medicines and falsifying data to win marketing approval for the drugs.
About the Author Reprints
